The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | A | Alimentary tract and metabolism | |
2 | A10 | Drugs used in diabetes | |
3 | A10A | Insulins and analogues | |
4 | A10AB | Insulins and analogues for injection, fast-acting |
Code | Title | |
---|---|---|
A10AB01 | Insulin (human) | |
A10AB02 | Insulin (beef) | |
A10AB03 | Insulin (pork) | |
A10AB04 | Insulin lispro | |
A10AB05 | Insulin aspart | |
A10AB06 | Insulin glulisine | |
A10AB30 | Combinations |
Active Ingredient | Description | |
---|---|---|
Insulin (human) |
The blood glucose lowering effect of insulin is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. |
|
Insulin (pork) |
|
|
Insulin aspart |
The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. Insulin aspart produces a more rapid onset of action compared to soluble human insulin, together with a lower glucose concentration, as assessed within the first four hours after a meal. Insulin aspart has a shorter duration of action compared to soluble human insulin after subcutaneous injection. |
|
Insulin glulisine |
Insulin glulisine is a recombinant human insulin analogue that is equipotent to regular human insulin. Insulin glulisine has a more rapid onset of action and a shorter duration of action than regular human insulin. |
|
Insulin lispro |
The primary activity of insulin lispro is the regulation of glucose metabolism. |
Title | Information Source | Document Type | |
---|---|---|---|
ACTRAPID Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
ADMELOG Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
APIDRA Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
HUMALOG 100 units/ml Solution for injection in vial / Cartridge / KwikPen - Junior KwikPen | European Medicines Agency (EU) | MPI, EU: SmPC | |
HUMALOG 200 units/ml Solution for injection KwikPen pre-filled pen | European Medicines Agency (EU) | MPI, EU: SmPC | |
HUMALOG Mix25 100 units/ml Suspension for injection in vial / cartridge / KwikPen pre-filled pen | European Medicines Agency (EU) | MPI, EU: SmPC | |
HUMALOG Mix50 100 units/ml Suspension for injection in cartridge / KwikPen pre-filled pen | European Medicines Agency (EU) | MPI, EU: SmPC | |
HUMULIN I Suspension for injection in a vial | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
HYPURIN Suspension for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
LIPROLOG Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
LYUMJEV Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
NOVORAPID Solution for injection in vial / Cartridge / Pre-filled pen | European Medicines Agency (EU) | MPI, EU: SmPC |